期刊文献+

血流灌注加血液透析治疗尿毒症继发性甲状旁腺功能亢进症的疗效观察 被引量:2

下载PDF
导出
摘要 目的 观察血流灌注加血液透析治疗尿毒症继发性甲状旁腺功能亢进症的疗效。方法将尿毒症继发性甲状旁腺功能亢进患者46例随机分成观察组及对照组,各23例,观察组予1周3次血液灌流串联血液透析治疗;对照组行常规1周3次血液透析治疗。1周后,比较两组血清全段甲状旁腺激素(PTH)和皮肤瘙痒、睡眠及肌无力等症状改善情况。结果血流灌注加血液透析治疗组1周后患者的甲状旁腺激素显著下降,与对照组比较差异有统计学意义(P〈0.05),且皮肤瘙痒、肌无力等症状好转,睡眠改善。结论1周3次血液灌流加血液透析可明显降低尿毒症患者的PTH浓度,较快改善患者症状,表明血流灌注串联血液透析治疗尿毒症继发性甲状旁腺功能亢进症有比较满意的疗效。 Objective To investigate the effects of combined hemoperfusion and hemodialysis in uremia patients complicated with secondary hyperparathyroidism. Methods 46 uremia patients complicated with secondary hyperparathyroidism were randomly devided into two groups :23 patients were treated with combined hemoperfusion and hemodialysis 3 times in one week ;the other 23 patients were treated with hemodialysis 3 times in one week; The serum parathyroid hormone (PTH) level and clinical manifestation were observed before and after one week treatments. Results The serum parathyroid hormone (PTH) level was reduced significantly in the hemoperfusion and hemodialysis group ; compared with hemodialysis, the hemoperfusion and hemodialysis had better effect in PTH clearance ( P 〈 0.05 ), meanwhile, some clinical manifestation ( appetite, pruritus, inscmnia) improved. Conclusions 3 times hemoperfusion and hemodialysis in one week can effectively clear PTH and improve clinical manifestation.
出处 《浙江临床医学》 2009年第6期575-577,共3页 Zhejiang Clinical Medical Journal
关键词 血液灌流 血液透析 尿毒症 继发性甲状旁腺功能亢进症 Hemoperfusion Hemodialysis Uremia Secondary hyperparathyroidism
  • 相关文献

参考文献5

二级参考文献23

  • 1蒋建平,侯凡凡.维持性血液透析患者β_2-微球蛋白沉淀病[J].中国实用内科杂志,2001,21(4):240-241. 被引量:7
  • 2陶立坚,池田,孙明.1,25(OH)_2D_3口服冲击治疗透析患者继发性甲状旁腺功能亢进[J].中华肾脏病杂志,1995,11(4):216-217. 被引量:1
  • 3边小曦 杨启青 等.有关肾民生骨病早期诊断问题的探讨[J].创伤骨科学报,1993,3:194-196.
  • 4Lindberg J,Martin KJ, Gonzalez EA,et al. Clin Nephrol,2001 ;56(4):315 -23.
  • 5Sprague SM, Lerma E, McCormmick D, et al. Am J Kidney Dis,2001 ;38(5 Suppl 5):S51 -6.
  • 6Kim G, Sprague SM.Adv Ren Replace Ther,2002;9(3) :175- 183.
  • 7George R, Bailie,Curtis A. Johnsan. Seminara in Dialysis,2002; 15(5) :352 - 357.
  • 8Slatopolsky E, Finch J, Ritter C, et al. Am J Kidney Dis, 1998 ;32(2 Suppl 2) :S40- 7.
  • 9Eduardo S, Adriana D, Alex JB. Kidney International, 2002; 61 ( suppl 80) :S143 - S148.
  • 10George R, Bailie,Curtis A, et al. Serninars in Dialysis,2002; 15(5) :352- 357.

共引文献17

同被引文献26

  • 1李荣山,甄国华,程丽娟,邵珊,高仁义,李建萍,李元红,成秀芬,张渝,刘静.血液灌流对继发性甲状旁腺功能亢进的影响[J].中国血液净化,2005,4(5):277-278. 被引量:25
  • 2<活性维生素D的合理应用>专家协作组.活性维生素D在慢性肾脏病继发性甲旁亢中合理应用的专家共识(修订版)[J].中华肾脏病杂志,2005,21(11):698-699. 被引量:97
  • 3黎磊石,刘志红.中国肾脏病学[M].人民军医出版社,2008,1831-1835.
  • 4Lein NW,Hulberg-Shearon TE,Strawderman RL.et al.Which causes of death are related to hyperphosphatemia in hemodialysis patients[J].J Am Soc Nephrol,1998,9:217.
  • 5London GM,Marcy J,Marchais SJ,et al.Arterial cacitlcations and bone histomorphometry in end-stage renal disease.J Am sol Nephrprol,2004,15:1943~1951.
  • 6Urena-Torres P,Metzger M,Haymann JP,et al.Association of Kidney function,vitamin D deficiency,and circulating markers ofmineral and bone disorders in CKD [J].Am JKidney Dis,2011,58:544-553.
  • 7Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the pro- gression of coronary and aortic calciication in hemodialysis pa- tients[J].Kidney Int 2002,62: 245-252.
  • 8Dyer, Christopher A.Safety and tolerability of paricalcitol in pa- tients with chronic kidney disease[J].Expert Opinion on drug safety,2013,12(5) : 717 -728.
  • 9G.Jean, T.Vanel, et al.Prevention of secondary hyperparathy- roidism in hemodialysis patients:The key role of native vitamin D supplementation[J].Hemodialysis International,2010,14(14): 486-491.
  • 10Eid M E1-Shafey,Ali E Alsahow,et al.Cinacalcet Hydrochloride- Therapy for Secondary Hyperparathyroidism in Hemodialysis Pa- tients[J].TherapeuticApheresis and Dialysis TherapeuticAphere- sis and Dialysis 2011,15(6):547-555.

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部